The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
In patients with polycythemia vera receiving standard of care therapy, treatment with rusfertide continued to yield a statistically significant reduction in the mean
Epcoritamab in combination with rituximab and lenalidomide has the potential to be the new standard of care in patients with second-line follicular lymphoma,
Extramedullary disease (EMD) in multiple myeloma (MM) is associated with significantly higher rates of severe toxicity following B-cell maturation antigen (BCMA)-targeted CAR T-cell
In this interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Sundar Jagannath, MD, professor of medicine at
SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, MD, director of clinical
2027-2028 SOHO President-elect Valeria Santini, MD, grew up in Florence, where she says the city’s beauty, history, and art shaped her entire outlook
Despite ALL treatment progress, patients still need safer, more effective options Novel agents have transformed outcomes for patients with relapsed or refractory acute
Dr. Vose will be speaking at 12:30 pm Central time on November 20, 2025, during SBBC. At 12:55 pm Central time, attendees can
In this SOHO Insider podcast, Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, and Niels W C
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval
